VMRK

Vivmark Residential

$63.04

+0.59%
Nov 20, 2026
Bobby Quantitative Model
Vivmark Residential is a residential REIT that owns and operates a high-quality apartment portfolio of roughly 184,000 units concentrated in major metropolitan markets across New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest, supplemented by a $4.4 billion development pipeline. With a market capitalization near $48 billion and only about 3,000 employees managing a geographically dense, supply-constrained coastal footprint, Vivmark positions itself as a blue-chip, institutional-quality owner of gateway-market rental housing rather than a diversified or Sun Belt growth REIT. The current investor debate centers on a sharply negative reported third-quarter GAAP result — a $735 million net loss driven by a large non-cash impairment/other-expense charge — set against resilient property-level fundamentals, with revenue up 52.8% year over year on a reported basis and a 4.4% dividend yield that keeps income investors engaged. Bulls point to the coastal supply moat, embedded development pipeline, and a 7.9-point one-month relative strength advantage over the S&P 500, while bears focus on the earnings quality of the reported loss, a payout ratio near 94%, and a valuation that screens rich on forward earnings.

People also watch

Essex Property Trust, Inc.

Essex Property Trust, Inc.

ESS

Analysis
Invitation Homes

Invitation Homes

INVH

Analysis
Sun Communities

Sun Communities

SUI

Analysis
MAA

MAA

MAA

Analysis
Equity Lifestyle Properties, Inc.

Equity Lifestyle Properties, Inc.

ELS

Analysis

BobbyInvestment Opinion: Should I buy VMRK Today?

Rating: Hold. Vivmark is a high-quality coastal multifamily REIT trading at roughly fair value — the $71.72 average analyst target implies only +11.7% upside from $64.22, the 20-analyst consensus splits 10 Buy / 12 Hold / 0 Sell with a recommendation mean of 2.18, and the near-term evidence (a $735.1 million Q3 net loss, a 93.5% payout ratio, and -$219.8 million of quarterly free cash flow) is not yet offset by confirmed core FFO growth. The core thesis is that the Q3 impairment is a non-cash accounting event against a portfolio earning premium rents in supply-constrained gateway markets, but the market is already pricing most of that recovery.

Supporting evidence is genuinely mixed. On the positive side, Q3 revenue of $1.195 billion grew 52.8% year over year, gross margin held at 62.4% with EBITDA of $274.0 million, trailing free cash flow is $581.6 million, and the 4.38% dividend yield sits near the high end of its historical band while price-to-book of 2.16x sits near the low end of its 2.0x–3.1x range — historically value-entry markers. Against that, the forward PE of 41.6x versus trailing 21.2x implies the market expects earnings to roughly halve, the PEG of 2.41 signals the stock is priced for defensiveness rather than growth, and the 93.5% payout ratio leaves essentially no cushion for the $4.4 billion development pipeline. The 12-point twelve-month underperformance versus the S&P 500 (+0.29% vs. +12.27%) reflects that the market has not yet rewarded the story.

The biggest risks that could invalidate the thesis are (1) the Q3 revenue step-up proving non-recurring rather than FFO-accretive, (2) a dividend cut or dilutive equity raise forced by the 93.5% payout ratio and negative quarterly free cash flow, and (3) further write-downs following the $1.37 billion other-expense charge. This Hold would upgrade to Buy if core FFO growth confirms the Q3 revenue jump is durable and the stock breaks above the $68.14 resistance on volume toward the $71.72 average target, or if price-to-book compresses toward 2.0x with the dividend intact; it would downgrade to Sell if the payout ratio forces a dividend cut or if the stock breaks below the $59.29 October low. Verdict: fairly valued relative to its own history and the analyst consensus, neither a clear bargain nor an obvious outlier.

Sign up to view all

VMRK 12-Month Price Forecast

Vivmark presents a balanced risk/reward: the 52.8% Q3 revenue jump, positive $274.0 million EBITDA, and 62.4% gross margin support the bull case that the $735.1 million loss is a non-cash impairment, while the 93.5% payout ratio, negative quarterly free cash flow, and 12 points of twelve-month underperformance anchor the bear case. The stock sits mid-range at $64.22, roughly 47% of its 52-week range, with a 7.89-point one-month relative-strength advantage suggesting money is rotating back in, but the burden of proof remains on converting that bounce into a breakout above $68.14. Analyst sentiment is cautiously bullish — no Sells but a majority of Holds — implying fair value is roughly where the stock trades. I would upgrade to bullish if Q4 discloses core FFO growth confirming the revenue step-up is durable and the impairment is confirmed non-recurring, and downgrade to bearish if the payout ratio forces a dividend cut or the stock breaks below the $59.29 October low.

Historical Price
Current Price $63.04
Average Target $67.36
High Target $80.00
Low Target $57.57

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Vivmark Residential's 12-month outlook, with a consensus price target around $71.77 and implied upside of +13.8% versus the current price.

Average Target

$71.77

23 analysts

Implied Upside

+13.8%

vs. current price

Analyst Count

23

covering this stock

Price Range

$63 - $80

Analyst target range

Buy
10 (44%)
Hold
13 (57%)
Sell
0 (0%)

Coverage is broad and moderately constructive: 20 analysts cover Vivmark with a distribution of 10 Buy, 12 Hold, and 0 Sell, yielding a consensus recommendation of "buy" but a recommendation mean of 2.18 that leans closer to Hold than a strong Buy. The average target price of $71.72 implies roughly +11.7% upside from the current $64.22, and the consensus revenue estimate of $3.50 billion (range $3.26 billion to $3.79 billion) suggests analysts expect the Q3 revenue step-up to persist. Sentiment is best described as cautiously bullish — no outright sells, but a majority of Hold ratings signals that analysts see fair value as roughly where the stock trades, with upside contingent on execution.

The target range of $63.00 to $80.00 is wide relative to the $64.22 price, with the low target essentially at the current price and the high target implying roughly 24.6% upside — a spread that signals genuine disagreement about the durability of the Q3 revenue jump and the earnings impact of the impairment. The high target likely assumes the Q3 loss is a one-time non-cash event, that development deliveries drive FFO growth, and that the stock re-rates toward the upper end of its historical book-value band; the low target effectively prices in flat core growth, elevated capex, and a payout ratio near 94% that limits dividend growth. Institutional ratings show a stable-to-positive pattern — UBS reiterated Buy on November 10, Wells Fargo maintained Overweight on October 19, and no downgrades appear in the recent record — but the prevalence of Neutral/Sector Perform stances from Cantor Fitzgerald, RBC, Barclays, Piper Sandler, BTIG, and Scotiabank confirms that conviction is concentrated among a minority of the covering group.

Drowning in data?

Find the real signal!

Bulls vs Bears: VMRK Investment Factors

The bear case currently has slightly stronger near-term evidence: the reported $735.1 million quarterly loss, a 93.5% payout ratio, negative quarterly free cash flow of -$219.8 million, and 12 points of twelve-month underperformance are concrete and quantifiable, whereas the bull case rests on interpreting the loss as non-cash and on a revenue jump whose durability is unproven. That said, the bulls have real ammunition — positive EBITDA of $274.0 million, a 62.4% gross margin, a 2.16x price-to-book near the low end of its historical range, and a 7.89-point one-month relative-strength advantage — which is why 20 analysts split 10 Buy / 12 Hold with zero Sells. The single most important tension is whether the 52.8% Q3 revenue step-up is a durable, FFO-accretive transaction or a one-off that inflates the top line while diluting per-share cash flow; if core FFO growth confirms the former, the stock re-rates toward the $71.72 average target, but if it is the latter, the 93.5% payout ratio becomes the binding constraint. Until core FFO is disclosed and the impairment is confirmed as non-recurring, the risk/reward is balanced rather than compelling.

Bullish

  • Coastal supply moat supports pricing: Vivmark's ~184,000 units are concentrated in supply-constrained gateway markets (New England, NY/NJ, D.C., California, Pacific Northwest), where new supply is structurally limited. The 46.3% gross margin and 36.1% trailing net margin confirm the portfolio earns premium rents rather than competing on volume.
  • Revenue step-change of 52.8% YoY: Q3 2026 revenue of $1.195 billion grew 52.8% from $782.4 million in Q3 2025, and rose sequentially from $779.8 million in Q1 and $785.0 million in Q2. The step-change points to a material transaction or development deliveries, and the $3.50 billion consensus revenue estimate implies analysts expect it to persist.
  • Q3 loss is non-cash, not operational: The $735.1 million net loss was driven by $1.37 billion of other expenses and a $741.6 million operating loss, yet EBITDA remained positive at $274.0 million and gross margin was a healthy 62.4%. Prior quarters were solidly profitable (Q2 net income $114.1 million, Q1 $90.1 million), consistent with an impairment rather than deteriorating rental economics.
  • Analyst targets imply 11.7% upside: The $71.72 average target implies roughly +11.7% from the $64.22 price, with a high target of $80.00 (~24.6% upside) and a low of $63.00 essentially at the current price. Coverage is 10 Buy / 12 Hold / 0 Sell, so no analyst sees outright downside.

Bearish

  • Payout ratio of 93.5% leaves no cushion: Dividends paid of $253.3 million in Q3 exceeded operating cash flow of $258.8 million only marginally, and the 93.5% payout ratio means the 4.38% yield is vulnerable to any sustained capex increase or NOI decline. This structurally caps dividend growth and limits the income-investor case.
  • Negative quarterly free cash flow: Q3 operating cash flow of $258.8 million against capital expenditures of $478.6 million produced -$219.8 million of quarterly free cash flow as the $4.4 billion development pipeline ramped. The TTM free cash flow of $581.6 million masks this quarterly cash burn.
  • Earnings quality and volatility: Diluted EPS swung from +$0.30 in Q2 to -$1.27 in Q3, and the forward PE of 41.6x versus trailing 21.2x implies the market expects earnings to roughly halve. The $1.37 billion other-expense charge raises questions about asset carrying values that GAAP net income alone cannot answer.
  • Twelve-month relative underperformance: The 1-year price change of just +0.29% versus the S&P 500's +12.27% represents roughly 12 points of underperformance, and the -12.99% max drawdown shows the stock has digested rather than trended. At $64.22 the stock sits at only ~47% of its 52-week range, mid-range with no clear directional resolution.

VMRK Technical Analysis

Vivmark is in a choppy, range-bound consolidation rather than a clean trend: the stock sits at $64.22, roughly 6.7% below its 52-week high of $71.50 and about 11.6% above its 52-week low of $57.57, placing it at approximately 47% of its 52-week range — squarely mid-range, which signals neither momentum-driven overextension nor a falling-knife value setup. The 1-year price change of just +0.29% versus the S&P 500's +12.27% confirms meaningful relative underperformance over twelve months, and a maximum drawdown of -12.99% shows the stock has spent the year digesting rather than trending. In practical terms, this is a stock that has been building a base, and the mid-range positioning means the risk/reward is defined by which boundary breaks first.

Short-term momentum has turned decisively positive and is diverging from the flat long-term trend: the stock is up 5.63% over the past month against a -2.26% decline for SPY, a 7.89-point relative-strength spread that marks a clear rotation of money into the name. That rally followed a September slide from $66.32 on September 14 to a $59.29 low on October 7 — a roughly 10.6% drawdown — and the subsequent recovery to $64.22 has retraced most of that decline, with the November 5–9 push from $63.72 to $66.14 accompanied by visibly stronger daily advances. This pattern of a sharp pullback followed by a higher-low recovery is characteristic of mean reversion within a base rather than a trend reversal, but the divergence between a +5.6% one-month move and a +0.3% one-year move means the burden of proof is on the bulls to convert this bounce into a breakout.

Key technical levels are well defined: resistance sits at the $66.14–$68.14 zone (the November 9 close and the August 24 swing high) with the 52-week high of $71.50 as the major ceiling, while support rests at the October 7 low of $59.29 and the 52-week low of $57.57. A breakout above $68.14 on volume would signal the base is resolving higher and open a path toward $71.50, whereas a breakdown below $59.29 would confirm the September–October downtrend and put the $57.57 low in play. Volatility is modest — beta of 0.549 means the stock moves roughly 45% less than the market, which supports larger position sizing for a given risk budget but also implies the stock will lag in sharp rallies; the short ratio of 4.28 days-to-cover indicates moderate bearish positioning that could add fuel to an upside breakout.

Beta

0.55

0.55x market volatility

Max Drawdown

-13.0%

Largest decline past year

52-Week Range

$58-$72

Price range past year

Annual Return

—

Cumulative gain past year

PeriodVMRK ReturnS&P 500
1m+1.7%-9.7%
3m-5.6%-9.9%
6m—-7.5%
1y—+4.7%
ytd—+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

VMRK Fundamental Analysis

The revenue trajectory is strong but requires careful reading: Q3 2026 revenue of $1.195 billion grew 52.8% year over year versus $782.4 million in Q3 2025, a jump that far exceeds organic rent growth and points to portfolio expansion, acquisitions, or development deliveries rather than same-store pricing power alone. Sequentially, revenue rose from $779.8 million in Q1 to $785.0 million in Q2 and then to $1.195 billion in Q3, a step-change that suggests a material transaction closed during the quarter. The reported segment detail is thin — other rental income of $26.4 million, other revenue of $19.5 million, and parking revenue of $6.9 million — so the bulk of the top line is core apartment rents, and the investment case hinges on whether the Q3 revenue step-up is durable and accretive to per-share cash flow rather than merely larger.

Profitability is the central controversy: Q3 2026 produced a net loss of $735.1 million and diluted EPS of -$1.27, driven by $1.37 billion of other expenses and a $741.6 million operating loss, despite a healthy 62.4% gross margin and $746.4 million of gross profit. The loss is not an operating-margin collapse — EBITDA was still positive at $274.0 million, and the prior three quarters were solidly profitable (Q2 net income $114.1 million, Q1 $90.1 million, Q4 2025 $382.1 million) — which points to a non-cash impairment or write-down rather than a deterioration in rental economics. The trailing net margin of 36.1% and operating margin of 36.3% remain strong for a residential REIT, but the volatility of reported earnings (EPS swinging from +$0.30 to -$1.27 in one quarter) means investors should focus on core FFO and cash flow rather than GAAP net income.

Balance sheet and cash flow are adequate but not fortress-like: debt-to-equity is 0.80, ROE is 10.1%, and trailing free cash flow is $581.6 million, yet the current ratio of 0.047 is extraordinarily low and reflects a REIT structure where current liabilities are funded by operating cash flow and revolver capacity rather than liquid current assets. Q3 operating cash flow was $258.8 million against capital expenditures of $478.6 million, producing negative quarterly free cash flow of -$219.8 million as development spending ramped, while dividends paid of $253.3 million exceeded operating cash flow for the quarter. The payout ratio of 93.5% and 4.38% dividend yield leave little cushion, meaning the dividend is supported by the recurring cash flow base but vulnerable to any sustained increase in capex or decline in NOI.

Quarterly Revenue

$1.2B

2026-09

Revenue YoY Growth

+52.8%

YoY Comparison

Gross Margin

62.4%

Latest Quarter

Free Cash Flow

$581633000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Other Rental Income
Other Revenue
Parking Revenue

Open an Account, get $2 TSLA now!

Valuation Analysis: Is VMRK Overvalued?

Because Vivmark's trailing net income is positive on a TTM basis (trailing PE of 21.2x) but the most recent quarter was a loss, the PE ratio is distorted and I lead with the price-to-book and EV/EBITDA framework that REIT investors typically use, while noting the PE for context. The trailing PE of 21.2x versus a forward PE of 41.6x implies the market expects earnings to roughly halve next year — a gap that is almost certainly an artifact of the Q3 impairment rolling through the trailing base rather than a genuine growth signal, and it makes the forward multiple unreliable. On the metrics that matter for a residential REIT, the stock trades at 2.16x book, 13.9x EV/EBITDA, and 19.3x EV/sales, with a 7.7x PS ratio that reflects the capital-intensive, high-margin nature of the asset base.

Peer comparison is constrained because the provided valuation dataset does not include industry-average multiples, so a precise premium/discount spread cannot be quantified; based on the available figures, a 2.16x price-to-book and 13.9x EV/EBITDA are broadly in line with where high-quality coastal multifamily REITs have historically traded, neither a clear bargain nor an obvious outlier. The 4.38% dividend yield is competitive for the sector and provides a valuation floor for income buyers, while the 36.1% net margin and 46.3% gross margin support the argument that the asset base earns premium rents in supply-constrained markets. The PEG ratio of 2.41 suggests the market is paying up relative to expected growth, which is consistent with a defensive, low-beta name rather than a growth story.

Historical context is the most revealing lens: the stock's own PE has ranged from roughly 15.6x to 61.6x over the past three years, and the current 21.2x sits in the lower-middle of that band, well below the 2025 peak of 61.6x and the 2024 highs above 47x. Price-to-book of 2.16x is near the low end of its historical 2.0x–3.1x range, and the dividend yield of 4.38% is near the high end of its historical 0.7%–1.1% band — a combination that historically has marked value-oriented entry points rather than fundamental deterioration. The caveat is that the Q3 loss distorts trailing ratios, so the apparent cheapness on book value should be confirmed by core FFO growth before being treated as a genuine discount.

PE

21.2x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 16x~62x

vs. Industry Avg

28.1x

Industry PE ~28.1x*

EV/EBITDA

13.9x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on cash-flow coverage and earnings quality. The 93.5% payout ratio means dividends of $253.3 million in Q3 consumed nearly all of the $258.8 million in operating cash flow, while capital expenditures of $478.6 million drove quarterly free cash flow to -$219.8 million as the $4.4 billion development pipeline ramped. A current ratio of 0.047 leaves essentially no liquid buffer, so the company depends on revolver capacity and continued operating cash flow to fund current liabilities, and debt-to-equity of 0.80 with $123.8 million of quarterly interest expense adds refinancing sensitivity. The $1.37 billion other-expense charge that produced the $735.1 million net loss also raises the possibility of further write-downs if coastal asset values are reappraised.

Market and competitive risks are dominated by valuation and relative performance. The forward PE of 41.6x against a trailing 21.2x implies the market expects earnings to roughly halve, and a PEG ratio of 2.41 signals the stock is priced for defensive stability rather than growth; if core FFO disappoints, multiple compression is the primary transmission channel. The stock's beta of 0.549 means it moves roughly 45% less than the market, which cushions drawdowns but guarantees it lags in sharp rallies — a real opportunity cost given the S&P 500's +12.27% one-year return versus Vivmark's +0.29%. The 12 Hold ratings out of 20 analysts, including Neutral/Sector Perform stances from Cantor Fitzgerald, RBC, Barclays, Piper Sandler, BTIG, and Scotiabank, confirm that conviction is concentrated in a minority and that a single disappointing quarter could tip the consensus toward Hold.

The worst-case scenario is a chain in which the Q3 revenue step-up proves non-recurring, core FFO stagnates, the 93.5% payout ratio forces a dividend cut or a dilutive equity raise to fund the development pipeline, and the impairment is followed by further write-downs that erode book value below the 2.16x multiple. In that sequence, the stock would retest the October 7 low of $59.29 and then the 52-week low of $57.57, representing roughly -7.7% and -10.4% from the current $64.22, with the analyst low target of $63.00 offering little support. A more severe outcome — a dividend cut combined with multiple compression toward the low end of the historical PE band — could extend losses toward the -12.99% max drawdown already experienced this year, implying a decline to roughly $55.90. The realistic downside from here is therefore in the -8% to -13% range, modest in absolute terms because of the low beta and 4.38% yield floor, but meaningful relative to the +11.7% upside to the average target.

FAQ

Ranked by severity, the first risk is dividend sustainability: a 93.5% payout ratio with dividends of $253.3 million against $258.8 million of quarterly operating cash flow and -$219.8 million of quarterly free cash flow leaves essentially no cushion, and a cut would hit both the 4.38% yield and the valuation floor simultaneously. Second is earnings quality and further write-downs — the $1.37 billion other-expense charge produced a $735.1 million net loss and a $741.6 million operating loss, and a second impairment would erode book value below the 2.16x multiple that anchors the value case. Third is balance-sheet liquidity: a current ratio of 0.047 is extraordinarily low, debt-to-equity is 0.80, and $123.8 million of quarterly interest expense makes refinancing costs a live sensitivity. Fourth is valuation and relative-performance risk — the forward PE of 41.6x versus trailing 21.2x leaves room for multiple compression if core FFO disappoints, and the stock's +0.29% one-year return versus the S&P 500's +12.27% shows it has already lagged badly through a strong market, a pattern the 0.549 beta will perpetuate in rallies.

The base case carries 55% probability with a $63.00–$71.72 target range, assuming core FFO grows low-to-mid single digits consistent with the $3.50 billion consensus revenue estimate, the 93.5% payout ratio holds without a cut, and the stock stays in its $59–$68 range with a drift toward the $71.72 average target. The bull case at 25% probability targets $71.72–$80.00 and requires confirmation that the Q3 revenue step-up is durable and FFO-accretive, that the $1.37 billion charge is a one-time non-cash impairment, and a breakout above $68.14 on volume. The bear case at 20% probability targets $57.57–$63.00 and assumes the revenue jump proves non-recurring, forcing a dividend cut or dilutive equity raise and further write-downs, with a severe outcome near $55.90 consistent with the -12.99% max drawdown. The base case is most likely because it matches the current 10 Buy / 12 Hold / 0 Sell split and recommendation mean of 2.18; the key assumption is that the impairment is non-cash and core FFO is stable.

The answer depends on which multiple you trust, because the Q3 impairment distorts trailing earnings. The trailing PE of 21.2x versus a forward PE of 41.6x implies the market expects earnings to roughly halve, which is almost certainly an artifact of the $1.37 billion charge rolling through the trailing base rather than a genuine growth signal. On REIT-appropriate metrics, the stock trades at 2.16x book, 13.9x EV/EBITDA, 19.3x EV/sales, and a 7.7x PS ratio, with a PEG of 2.41 signaling the market is paying for defensiveness rather than growth. Against its own history, 2.16x book sits near the low end of the 2.0x–3.1x range and the 4.38% yield sits near the high end of its historical band, historically value-entry markers, while the 21.2x PE sits in the lower-middle of a three-year 15.6x–61.6x band. The provided dataset lacks industry-average multiples, so a precise peer spread cannot be quantified, but the overall picture is fairly valued to modestly undervalued on book and yield, and expensive on forward earnings — the market is pricing in a non-recurring impairment and stable core FFO, not growth.

The risk/reward is balanced rather than compelling at $64.22. Upside to the $71.72 average analyst target is only about +11.7%, with a high target of $80.00 (~24.6%) and a low target of $63.00 essentially at the current price, while the realistic downside runs to the $59.29 October low (-7.7%) and the $57.57 52-week low (-10.4%), with a dividend-cut scenario implying roughly $55.90 (-13%). The 4.38% dividend yield and 2.16x price-to-book near the low end of its 2.0x–3.1x historical range provide a valuation floor, and the 10 Buy / 12 Hold / 0 Sell split means no analyst sees outright downside. However, the 93.5% payout ratio, -$219.8 million of quarterly free cash flow, and a $735.1 million quarterly net loss mean the burden of proof is on management to show the Q3 revenue jump is durable. It is a reasonable buy for income-oriented investors with a 12–24 month horizon who want a low-beta (0.549) yield vehicle, and a poor buy for anyone seeking near-term capital appreciation until the stock clears $68.14 on volume.

This is a long-term income holding, not a short-term trading vehicle. The 0.549 beta means the stock moves roughly 45% less than the market, which dampens both drawdowns and rallies, and the +0.29% one-year return versus the S&P 500's +12.27% shows there is little momentum to trade; the -12.99% max drawdown and mid-range positioning at roughly 47% of the 52-week range confirm a base-building pattern rather than a trend. The 4.38% dividend yield is the primary return driver and is best harvested over time, though the 93.5% payout ratio means dividend growth will be minimal and the yield is not risk-free. Earnings visibility is moderate — the Q3 GAAP loss makes reported numbers unreliable, so investors must track core FFO, which is disclosed quarterly. A suggested minimum holding period is 12–24 months, long enough for the impairment to roll out of the trailing base and for development deliveries to contribute NOI; short-term traders should wait for a confirmed breakout above $68.14 or a retest of $59.29 before acting.